Your browser doesn't support javascript.
loading
Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Lippman, M E; Krueger, K A; Eckert, S; Sashegyi, A; Walls, E L; Jamal, S; Cauley, J A; Cummings, S R.
Affiliation
  • Lippman ME; Osteoporosis Research Program, Women's College Hospital, Toronto, Ontario, Canada. lippmanm@umich.edu
J Clin Oncol ; 19(12): 3111-6, 2001 Jun 15.
Article in En | MEDLINE | ID: mdl-11408508
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis / Breast Neoplasms / Raloxifene Hydrochloride / Selective Estrogen Receptor Modulators / Estrogens Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2001 Document type: Article Affiliation country: Canadá Country of publication: Estados Unidos
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis / Breast Neoplasms / Raloxifene Hydrochloride / Selective Estrogen Receptor Modulators / Estrogens Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2001 Document type: Article Affiliation country: Canadá Country of publication: Estados Unidos